Compare Innoviva, Inc. (INVA) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock

Innoviva, Inc. (INVA) offers the better valuation at 6.7x trailing P/E (11.3x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc. (INVA) is the cheapest at 6.7x versus Vertex Pharmaceuticals Incorporated at 30.9x. On forward P/E, Innoviva, Inc. is actually cheaper at 11.3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1.10x versus Vertex Pharmaceuticals Incorporated's 2.95x — a reasonable growth-adjusted valuation.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +128.0%, compared to +101.2% for Innoviva, Inc. (INVA). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +436.2% versus INVA's +85.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc. (INVA) is the lower-risk stock at 0.07β versus Vertex Pharmaceuticals Incorporated's 0.44β — meaning VRTX is approximately 526% more volatile than INVA relative to the S&P 500.

Innoviva, Inc. (INVA) is the more profitable company, earning 63.8% net margin versus 32.9% for Vertex Pharmaceuticals Incorporated — meaning it keeps 63.8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 38.5% for INVA. At the gross margin level — before operating expenses — VRTX leads at 86.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1.10x versus Vertex Pharmaceuticals Incorporated's 2.95x. A PEG below 1.5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11.3x forward P/E versus 24.5x for Vertex Pharmaceuticals Incorporated — 13.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 46.1% to $32.50.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc. (INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.07)). Both have compounded well over 10 years (INVA: +85.1%, VRTX: +436.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INVA is a small-cap deep-value stock; VRTX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.